Neurocrine Biosciences Initiates Phase 2 Clinical Study To Assess Crinecerfont In Children Aged 3 Months To Under 4 Years With Classic Congenital Adrenal Hyperplasia

Loading news article.

Neurocrine Biosciences Initiates Phase 2 Clinical Study To Assess Crinecerfont In Children Aged 3 Months To Under 4 Years With Classic Congenital Adrenal Hyperplasia | WAPE

Neurocrine Biosciences Initiates Phase 2 Clinical Study To Assess Crinecerfont In Children Aged 3 Months To Under 4 Years With Classic Congenital Adrenal Hyperplasia

Article summary

Related companies

Comments —